anti-claudin 18.2 antibody-drug conjugate azd4360
Generic: Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360
anti-claudin 18.2 antibody-drug conjugate azd4360: 1 clinical trial tracked.
anti-claudin 18.2 antibody-drug conjugate azd4360 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about anti-claudin 18.2 antibody-drug conjugate azd4360, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (1)
A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD4360 in Adult Participants With Advanced Solid Tumours
Primary endpoint: Incidence of participants with Dose-Limiting Toxicity (in dose escalation cohort), Adverse events (AEs) , Serious Adverse Events (SAEs) and AEs leading to discontinuation of AZD4360
Interventionalopen31 enrolledStarted 2025-04Completion 2027-1214 sites · China, Germany, Japan, United Kingdom…AstraZeneca